Back to today’s briefing

Story perspectives

New Molecule PZL-A Offers Hope for Mitochondrial Diseases

5/3/2025

33 4

Summary

Story summary

Dr. Jose Barrera-Paez's groundbreaking study uncovers the risks of base editing for mitochondrial diseases, highlighting its imprecision and the danger of harmful errors at elevated doses. In a hopeful twist, researchers have introduced PZL-A, a novel molecule aimed at POLG-related diseases, which shows potential in boosting mutant protein function. Clinical trials are now set to evaluate its safety and effectiveness in humans.

1 of 1

Story summary

Dr. Jose Barrera-Paez's groundbreaking study uncovers the risks of base editing for mitochondrial diseases, highlighting its imprecision and the danger of harmful errors at elevated doses. In a hopeful twist, researchers have introduced PZL-A, a novel molecule aimed at POLG-related diseases, which shows potential in boosting mutant protein function. Clinical trials are now set to evaluate its safety and effectiveness in humans.